Pharmacokinetic modelling of [99mTc]sestamibi and [99mTc]tetrofosmin enabled non-invasive estimation of cardiac sarcolemmal and mitochondrial membrane potentials in vivo.
Isolated Langendorff-perfused rat hearts and in vivo rats
Pharmacokinetic modelling of [99mTc]sestamibi and [99mTc]tetrofosmin
Baseline versus hyperkalaemic depolarization and mitochondrial uncoupling with CCCP
Quantitative estimation of sarcolemmal and mitochondrial membrane potentialssurrogate
This novel pharmacokinetic modelling approach using standard SPECT tracers enables the first non-invasive in vivo measurement of cardiac sarcolemmal and mitochondrial membrane potentials.
Abstract Transmembrane electrical potentials across the sarcolemmal () and mitochondrial () membranes are central to cellular excitability, metabolism and viability. However, their direct and quantitative measurement in vivo remains challenging. We established a quantitative kinetic modelling framework to estimate and independently from dynamic radiotracer data in the heart using the Nernst equation applied to the kinetics of the lipophilic cationic tracers 99m Tcsestamibi and 99m Tctetrofosmin. Parameters were estimated from high‐temporal‐resolution time–activity curves using non‐linear least squares and Markov chain Monte Carlo (MCMC) fitting. Experiments were performed in isolated Langendorff‐perfused rat hearts under baseline, hyperkalaemic depolarization and mitochondrial uncoupling with carbonylcyanide‐3‐chlorophenylhydrazone (CCCP) and in vivo using planar scintigraphy. In perfused hearts, baseline potentials were and (mean ± SD, n = 4). Increasing K + caused dose‐dependent depolarization of in agreement with Goldman–Hodgkin–Katz predictions, whereas remained stable. CCCP selectively depolarized to (300 n m ) and (600 n m ) with minimal effect on . In vivo , potentials were and ( n = 4), consistent with physiological values. This modelling approach enables the first non‐invasive, independent quantitative estimation of sarcolemmal and mitochondrial membrane potentials in vivo . It overcomes limitations of optical probes and, with high‐sensitivity single‐photon emission computed tomography and positron emission tomography (PET) systems (including total body PET), offers new opportunities to assess bioenergetic dysfunction in cardiovascular disease and beyond. image Key points Pharmacokinetic modelling of 99m Tcsestamibi and 99m Tctetrofosmin allowed independent estimation of sarcolemmal () and mitochondrial () membrane potentials ex vivo in the Langendorff perfused rat heart and in vivo in the rat heart. The method gave independent measures of membrane potentials ex vivo when depolarized with hyperkalaemic buffers or mitochondrial uncoupling. In vivo measurements of membrane potentials agreed with literature values, whereas was found to be less polarized ex vivo in the perfused heart. The method uses clinically available single‐photon emission computed tomography imaging agents that could be employed to measure these parameters in humans.
Building similarity graph...
Analyzing shared references across papers
Loading...
Edward C. T. Waters
Friedrich Baark
Matthew Orton
The Journal of Physiology
King's College London
Institute of Cancer Research
St Thomas' Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Waters et al. (Mon,) reported a other. Pharmacokinetic modelling of [99mTc]sestamibi and [99mTc]tetrofosmin enabled non-invasive estimation of cardiac sarcolemmal and mitochondrial membrane potentials in vivo.
www.synapsesocial.com/papers/69ba425c4e9516ffd37a290d — DOI: https://doi.org/10.1113/jp290295